Zobrazeno 1 - 10
of 29
pro vyhledávání: '"R Claramunt García"'
Publikováno v:
Late breaking abstracts.
Autor:
R Claramunt García, CL Muñoz Cid, A Sánchez Ruiz, N Garcia Gomez, M Merino Almazán, T Sánchez Casanueva
Publikováno v:
Late breaking abstracts.
Autor:
T Sánchez Casanueva, R Claramunt García, N Garcia Gomez, TM Rodríguez Martínez, M Merino Almazán, V López Pozas, L Labián Román, S Vizcaíno Velázquez, MG Fanega Acosta, E Navarro Maestre
Publikováno v:
Late breaking abstracts.
Publikováno v:
Section 4: Clinical pharmacy services.
Publikováno v:
Section 2: Selection, procurement and distribution.
Publikováno v:
Section 2: Selection, procurement and distribution.
Autor:
E Perez Cano, Y Jimenez López, CL Muñoz Cid, N Garcia Gomez, R Claramunt García, JF Marin Pozo
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Anti-PD-L1 immunotherapy is used to treat secondline or later non-small cell lung cancer (NSCLC). These monoclonal antibodies are the therapy of choice against NSCLC in routine clinical practice. Aim and objectives To evalua
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Apalutamide, enzalutamide and darolutamide have recently been approved for treating castration resistant non-metastatic prostate cancer (nmCRPC). The three drugs demonstrated efficacy over placebo in clinical trials, but the
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Apalutamide, enzalutamide and darolutamide have recently been approved for treating castration resistant non-metastatic prostate cancer (nmCRPC). The lack of direct comparisons makes the selection and positioning of these dr
Autor:
M Merino Almazan, R Claramunt García, I Caba Porras, Y Jimenez López, MI Sierra Torres, E Perez Cano
Publikováno v:
Section 3: Production and Compounding.
Background and importance Multiple food allergy (MFA), in its severe stage, is a pathology with nutritional and pharmacotherapeutic restrictions. Drug intolerance to available medicines and lack of alternatives can lead to magistral formulations. Aim